Win Motif Inhibitors for the Treatment of Cancer
A novel approach to the development of new and effective cancer treatment options.
Background:
The Mixed Lineage Leukemia 1 (MLL1) protein is a member of the SET1 family of proteins. Mutations of the MLL1 core complex leads to excessive di- and trimethylation of H3K4 which alters gene regulation. This has been linked to certain types of leukemia,...
Published: 5/13/2025
|
Inventor(s): Michael Cosgrove, Nilda Alicea-Velazquez, Stephen Shinsky
Keywords(s): #SUNYresearch, cancer therapy, Technologies
Category(s): Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Healthcare, Campus > Upstate Medical University
|